EVOLVING TRENDS IN REGULATORY SCIENCE: A COMPREHENSIVE ANALYSIS OF FDA NOVEL DRUG APPROVALS (2021–2024)

Dr. Nehanand*, Dr. Pankaj Gupta, Dr. Jasleen Kaur, Dr. Jyoti Maria, Dr. Naufal, Dr. Sahil Kumar

ABSTRACT

Background: The United States Food and Drug Administration (FDA) is internationally recognized for its pivotal role in protecting public health through the rigorous evaluation and approval of novel therapeutic agents. Over recent years, major legislative acts and policy initiatives—such as the Orphan Drug Act and PDUFA—have transformed the regulatory landscape by innovation, and predictability in drug development. Insightful, up-to-date analyses of regulatory trends are vital for understanding both scientific progress and policy impacts within modern drug approvals. Objectives: This study aims to systematically evaluate patterns and characteristics of FDA novel drug approvals from 2021 to 2024. The primary objectives are to quantify approval volumes, identify dominant therapeutic areas, classify drug types (small molecule vs. biologic), and assess reliance on expedited regulatory pathways such as First in Class, Orphan Drug, Fast Track, Breakthrough Therapy, and Priority Review designations. Further aims include analysis of approval predictability, access metrics, and visualization of sectoral trends to inform regulatory science, healthcare policy, and pharmaceutical innovation. Methods & Results: Using a curated dataset of 192 approvals, annual and therapeutic trends were mapped, with oncology, haematology, dermatology, and neurology accounting for a majority of new therapies. The use of expedited regulatory pathways remained consistently high, and biologics comprised a large share of novel approvals, illustrating the advancing shift to complex therapeutic technologies. Conclusions: The findings reinforce FDA’s unique and dynamic role in facilitating innovative drug development and rapid patient access to new treatment options, while offering a robust framework for future regulatory evaluation and global benchmarking.

Keywords: Regulatory Science, Biologics, Orphan Drugs, Drug Development, Pharmacovigilance.